Postmenopausal hormone therapy–also use of estradiol plus levonorgestrel‐intrauterine system is associated with an increased risk of primary fallopian tube carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|137|8|1947-1952

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.8, 2015-10, pp. : 1947-1952

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol

By Blumenfeld Z.   Boulman N.   Leiba R.   Siegler E.   Shachar S.   Linn R.   Levy Y.  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 67, Iss. 3, 2007-01 ,pp. : 257-263

Informa Healthcare

Access to resources Recommend Favorite

Assessment of a new system for primary site assignment in high‐grade serous carcinoma of the fallopian tube, ovary, and peritoneum

By  

HISTOPATHOLOGY, Vol. 67, Iss. 3, 2015-09 ,pp. : 331-337

John Wiley & Sons Inc

Access to resources Recommend Favorite

MRI for differentiating primary fallopian tube carcinoma from epithelial ovarian cancer

By  

JOURNAL OF MAGNETIC RESONANCE IMAGING, Vol. 42, Iss. 1, 2015-07 ,pp. : 42-47

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combination of drospirenone and estradiol: a new hormone therapy in postmenopausal women

By Huber Johannes C  

Women's Health, Vol. 3, Iss. 4, 2007-07 ,pp. : 409-415

Future Medicine

Access to resources Recommend Favorite

Hormone therapy administration in postmenopausal women and risk of stroke

By Renoux Christel   Suissa Samy  

Women's Health, Vol. 7, Iss. 3, 2011-05 ,pp. : 355-361

Future Medicine

Access to resources Recommend Favorite